Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
NEOG 
Neogen Corporation (NEOG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/22/2025: NEOG (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.17
1 Year Target Price $8.17
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 8.35% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.56B USD | Price to earnings Ratio - | 1Y Target Price 8.17 |
Price to earnings Ratio - | 1Y Target Price 8.17 | ||
Volume (30-day avg) 3 | Beta 1.98 | 52 Weeks Range 3.87 - 13.40 | Updated Date 12/22/2025 |
52 Weeks Range 3.87 - 13.40 | Updated Date 12/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -117.61% | Operating Margin (TTM) -7.69% |
Management Effectiveness
Return on Assets (TTM) -0.29% | Return on Equity (TTM) -39.71% |
Valuation
Trailing PE - | Forward PE 16 | Enterprise Value 2218197107 | Price to Sales(TTM) 1.76 |
Enterprise Value 2218197107 | Price to Sales(TTM) 1.76 | ||
Enterprise Value to Revenue 2.5 | Enterprise Value to EBITDA 25.07 | Shares Outstanding 217298626 | Shares Floating 205227687 |
Shares Outstanding 217298626 | Shares Floating 205227687 | ||
Percent Insiders 0.89 | Percent Institutions 111.89 |
Upturn AI SWOT
Neogen Corporation
Company Overview
History and Background
Neogen Corporation was founded in 1982 by James Herbert. The company has grown significantly through a combination of organic growth and strategic acquisitions. Its primary focus has been on developing and marketing products dedicated to food and animal safety. Over the years, Neogen has expanded its product portfolio to cover a wide range of diagnostic tests, sanitizers, and other related products for both the food production and animal health industries.
Core Business Areas
- Food Safety: This segment focuses on providing diagnostic test kits and complementary products for the detection of foodborne pathogens, natural toxins, allergens, drug residues, and sanitation concerns in food and feed. Products include ELISA tests, lateral flow devices, and culture media.
- Animal Safety: This segment offers a comprehensive range of products for the animal health market. This includes veterinary instruments, pharmaceuticals, vaccines, diagnostics, rodenticides, insecticides, and herd management solutions. It also encompasses genomics services for livestock and companion animals.
Leadership and Structure
Neogen Corporation is led by a management team with extensive experience in the food and animal safety industries. The company is structured around its core business segments, with dedicated teams for research and development, sales, marketing, and operations within each area. Specific leadership roles include CEO, CFO, and heads of various divisions and subsidiaries.
Top Products and Market Share
Key Offerings
- Diagnostic Test Kits (Food Safety): Neogen offers a wide array of rapid diagnostic tests for detecting pathogens (e.g., Salmonella, Listeria), allergens (e.g., gluten, peanuts), and toxins (e.g., mycotoxins) in food and ingredients. These are used by food manufacturers, processors, and regulatory bodies. Competitors include Romer Labs, Thermo Fisher Scientific, and Q Controls.
- Genomics Services (Animal Safety): Neogen provides DNA testing services for livestock and companion animals to identify genetic traits, improve breeding, and manage disease. This is a growing area with significant demand. Competitors include Zoetis, GeneSeek (a Neogen subsidiary), and other specialized genetic testing labs.
- Sanitizers and Disinfectants (Food and Animal Safety): The company offers a range of sanitizing and disinfecting products crucial for maintaining hygiene in food processing facilities and animal facilities. Competitors include Ecolab, Diversey, and multiple smaller chemical suppliers.
- Veterinary Instruments and Pharmaceuticals (Animal Safety): This includes a broad range of products for animal healthcare professionals, from surgical instruments to pharmaceuticals and vaccines. Competitors include Zoetis, Merck Animal Health, and Boehringer Ingelheim Animal Health.
Market Dynamics
Industry Overview
Neogen operates within the global food safety and animal health industries. The food safety market is driven by increasing consumer demand for safe food, stricter regulatory requirements, and a rise in foodborne illnesses. The animal health market is fueled by growing demand for protein, increasing pet ownership, and advancements in veterinary care and genomics.
Positioning
Neogen is well-positioned as a leading provider of comprehensive solutions for both food and animal safety. Its diversified product portfolio, strong brand recognition, and global distribution network are key competitive advantages. The company's focus on innovation and strategic acquisitions has allowed it to expand its market reach and product offerings.
Total Addressable Market (TAM)
The global food safety testing market is estimated to be tens of billions of dollars and is projected to grow significantly. The global animal health market is also valued in the tens of billions of dollars. Neogen, with its broad product lines and global presence, addresses a substantial portion of this TAM, particularly in specialized diagnostic and safety solutions.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio across food and animal safety.
- Strong brand recognition and established customer relationships.
- Global distribution network.
- Proven track record of successful acquisitions.
- Focus on innovation and R&D.
Weaknesses
- Reliance on a few key product lines or technologies.
- Potential integration challenges with acquisitions.
- Competition from larger, more diversified companies.
Opportunities
- Increasing global demand for food safety and traceability.
- Growth in the companion animal market and advanced genomics.
- Expansion into emerging markets.
- Development of new diagnostic technologies.
- Increased regulatory scrutiny driving demand for testing.
Threats
- Economic downturns impacting customer spending.
- Intensifying competition and price pressures.
- Changes in regulatory landscapes.
- Disruptive technological advancements from competitors.
- Supply chain disruptions.
Competitors and Market Share
Key Competitors
- Eurofins Scientific (ERF.PA)
- Thermo Fisher Scientific (TMO)
- SGS SA (SGSX.SW)
- Zoetis Inc. (ZTS)
- Merck & Co., Inc. (MRK) - Animal Health Division
Competitive Landscape
Neogen competes in a fragmented market with both large diversified players and smaller niche specialists. Its competitive advantages lie in its integrated approach to food and animal safety, its agility in making strategic acquisitions, and its strong customer relationships. However, it faces challenges from larger companies with greater financial resources and broader product portfolios.
Major Acquisitions
Hygiena International
- Year: 2020
- Acquisition Price (USD millions): 300
- Strategic Rationale: Strengthened Neogen's rapid diagnostic testing portfolio in food safety, particularly in environmental monitoring and allergen testing, and expanded its global footprint.
Elanco Animal Health's Companion Animal Diagnostics Business
- Year: 2023
- Acquisition Price (USD millions): 400
- Strategic Rationale: Significantly expanded Neogen's presence in the companion animal diagnostics market, adding new products and technologies, and increasing its market share in this growing segment.
Growth Trajectory and Initiatives
Historical Growth: Neogen has a well-established history of consistent growth, driven by its strategic acquisitions and its ability to expand market share within its core segments. The company has demonstrated a compound annual growth rate (CAGR) for revenue that is often impressive, reflecting its successful integration of acquired businesses and organic expansion of its product lines.
Future Projections: Analyst projections for Neogen's future growth are generally positive, with expectations of continued revenue expansion driven by new product introductions, market penetration in existing and new geographies, and further strategic acquisitions. Growth in the food safety market due to regulatory and consumer pressures, along with advancements in animal genomics, are key drivers for these projections.
Recent Initiatives: Recent initiatives include the acquisition of other companies to expand its product portfolio and market reach, investment in research and development for new diagnostic technologies, and the expansion of its international sales and distribution networks. The company also focuses on enhancing its digital capabilities and customer service offerings.
Summary
Neogen Corporation is a strong player in the essential food and animal safety sectors, benefiting from consistent demand and favorable industry trends. Its strategy of diversified product offerings and strategic acquisitions has fueled impressive historical growth. While facing competition, its established market position and innovation focus provide a solid foundation for continued success. Key for Neogen will be seamless integration of acquisitions and ongoing development of cutting-edge diagnostic solutions.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Neogen Corporation Investor Relations Website
- SEC Filings (10-K, 10-Q)
- Financial Data Providers (e.g., Bloomberg, Refinitiv, Yahoo Finance)
- Industry Research Reports
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. All data is based on publicly available information and may not be exhaustive or perfectly up-to-date. Market share percentages are estimates and may vary depending on the source and methodology. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neogen Corporation
Exchange NASDAQ | Headquaters Lansing, MI, United States | ||
IPO Launch date 1989-08-23 | CEO, President & Director Mr. Mikhael Nassif | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 2974 | Website https://www.neogen.com |
Full time employees 2974 | Website https://www.neogen.com | ||
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and unintended substances in human food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides software systems that help testers analyze and store results; natural toxin tests; rapid sanitation tests; culture and prepared media products; filter tests for microbial analysis of water; sample collection products; and food safety analysis laboratory services. This segment sells its products to the milling and grain, meat and poultry, ready-to-eat, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. Its Animal Safety segment provides reagents and test kits for use in immunoassay production, forensic and animal toxicology, and life science research, as well as colorimetric and chemiluminescent substrates; veterinary instruments and disposables; animal care and other products, including digestive aids and nutritional supplements; rodent and insect control products, and disinfectants; and genomics services, such as DNA genotyping, sequencing, and trait analysis for livestock and companion animals. This segment sells its products to companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.